Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Church who wrote (4444)	6/6/1998 6:15:00 AM
From: Stevie D	Read Replies (2) \| Respond to of 6136

Peter, You may want to look into H&Q Life sciences. Its a closed end fund that invests primarily in healthcare and bitech companies. I have read that 20% of their investments are in the early venture capital stages(not public yet) and I believe it is currently selling at discount to NAV(thats hard to gauge with non public cos). Symbol is HQL and I don't own any myself but I have been looking at it.

To: Peter Church who wrote (4444)	6/6/1998 11:44:00 AM
From: Gary L. Kepler	Respond to of 6136

Biotech funds. Check out Fidelity Select Healthcare (FSPHX)and Vanguard Specialty Health (VGHCX). Both have done well for me over the last 10 years or so. Invesco Strategic Health has not. The mutual fund route has been a whole lot more comfortable particularly in a tax sheltered environment because of the risk of tax gains resulting from redemptions in a major retrenchment - a la '87. In a non-tax sheltered environment, direct ownership of shares is best because you can time your redemptions and therefore your tax obligations. I bought my AGPH years ago at what I believe was a split adjusted 5 or 6. I have no intention of selling for many years when maybe it will be 200+. Good Luck